Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma

Clinical Cancer Research

Volumn 2, Issue 5, 1996, Pages 889-895

  Mohler, James L ^a,b   Chen, Yeqing ^a   Hamil, Katherine ^a   Hall, Susan H ^a   Cidlowski, John A ^b   Wilson, Elizabeth M ^a,b   French, Frank S ^a,b   Sar, Madhabananda ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; STROMA;

AGED; AMINOGLUTETHIMIDE; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KETOCONAZOLE; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; STROMAL CELLS;

EID: 0029996555     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer Statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
2. Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T., and Thompson, T. C. Association of transforming growth factor-β1 with prostate cancer: an immunohistochemical study. Hum. Pathol., 24: 4-9, 1993.
3. Kan, M., Wang, F., Xu, J., Crabb, J. W., Hou, J., and McKeehan, W. L. An essential heparin-binding domain in the fibroblast growth factor kinase. Science (Washington DC), 259: 1918-1921, 1993.
4. Yan, G., Fukabori, Y., McBride, G., Nikolaropolous, S., and McKeehan, W. L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell Biol., 13: 4513-4522, 1993.
5. Cunha, G. R., Alarid, E. T., Turner, T., Donjacour, A. A., Boutin, E. L., and Foster, B. A. Normal and abnormal development of the male urogenital tract: role of androgens, mesenchymal-epithelial interactions, and growth factors J. Androl , 13: 465-475, 1992.
6. Huggins, C., and Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293-297, 1941.
7. Gonor, S. E., Lakey, W. H., and McBlain, W. A. Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J. Urol., 131: 1196-1201, 1984.
8. Fentie, D. D. Lakey, W. H., and McBlain, W. A. Applicability of nuclear androgen receptor quantification to human prostatic adenocarcinoma. J. Urol., 135: 167-173, 1986.
9. Sadi, M. V., Walsh, P. C , and Barrack, E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer: comparison of receptor content and response to hormonal therapy. Cancer (Phila.), 67: 3057-3064, 1991.
10. Sadi, M. V., and Barrack, E. R. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Cancer (Phila.), 71: 2574-2580, 1993.
11. Worgul, T. J., Santen, R. J., Samojlik, E., Veldhuis, J. D., Lipton, A., Harvey, H. A., Drago, J. R., and Rohner, T. J. Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J. Urol., 129: 51-55, 1983.
12. Drago, J. R., Santen, R. J., Lipton, A., Worgul, T. J., Harvey, H. A., Boucher, A., Manni, A., and Rohner, T. J. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer (Phila.), 53: 1447-1450, 1984.
13. Jubelirer, S. J., and Hogan, T. High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature. J. Urol., 142: 89-91, 1989.
14. Labrie, F., Dupont, A., Giguere, M., Borsanyi, J-P., Lacourciere, Y., Mongette, G., Emond, J., and Bergeron, N. Benefits of combination therapy with flutamide in patients relapsing after castration. Br. J. Urol., 61: 341-346, 1988.
15. Cidlowski, J. A., Bellingham, D. L., Powell-Oliver, F. E., Lubahn, D. B., and Sar, M. Novel antipeptide antibodies to the human glucocorticoid receptor: recognition of multiple receptor forms in vitro and distinct localization of cytoplasmic and nuclear receptors. Mol. Endocrinol., 4: 1427-1437, 1990.
16. Miyamoto, K. K., McSherry, S. A., Dent, G. A., Sar, M., Wilson, E. M., French, F. S., Sharief, Y., and Mohler, J. L. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J. Urol., 149: 1015-1019, 1993.
17. Tan, J., Joseph, D. R., Quarmby, V. E., Lubahn, D. B., Sar, M., French, F. S., and Wilson, E. M. The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol. Endocrinol., 2: 1276-1285, 1988.
18. Schroder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K., and Pavone-Macaluso, M. The TNM classification of prostate cancer. Prostate, 4 (Suppl.): 129-138, 1992.
19. Gleason, D. F., Mellinger, G. T., and the Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol., 111: 58-64, 1974.
20. Towbin, H., Staehelin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
21. Harris, S. E., Harris, M. A., Rong, Z., Hall, J., Judge, S., French, F. S., Joseph, D. R., Lubahn, D. B., Simental, J. A., and Wilson, E. M. Androgen regulation of HBGF-1 (α FGF) mRNA and characterization of the androgen receptor mRNA in the human prostate carcinoma cell line- LNCaP/A-Dep. In: J. P. Karr, D. S. Coffey, R. G. Smith, and D. J. Tindall (eds.), Molecular and Cellular Biology of Prostate Cancer, pp. 315-330. New York: Plenum Publishing Co., 1991.
22. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
23. Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., and Barrack, E. R. Androgen receptor gene mutations in human prostate cancer. Proc. Natl. Acad. Sci USA, 89: 6319-6323, 1992.
24. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C. B., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
25. Lubahn, D. B., Joseph, D. R., Sar, M., Tan, J., Higgs, H. N., Larson, R. E., French, F. S., and Wilson, E. M. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol. Endocrinol., 2: 1265-1275, 1988.
26. Chang, C., Chodak, G., Sarac, E., Takeda, H., and Liao, S. Prostate androgen receptor: immunohistochemical localization and mRNA characterization. J. Steroid Biochem., 34: 311-313, 1989.
27. Ruizeweld de Winter, J. A., Trapman, J., Brinkmann, A. O., Boersma, W. J. A., Mulder, E., Schroeder, F. H., Claassen, E., and van der Kwast, T H. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J. Pathol., 161: 329-332, 1990
28. van der Kwast, T. H., Schalken, J., Ruizeweld de Winter, J. A., van Vroonhoven, C. C. J., Mulder, E., Boersma, W., and Trapman, J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer, 48: 189-193, 1991.
29. Masai, M., Sumiya, H., Akimoto, S., Yatani, R., Chang, C. S., Liao, S. S., and Shimazaki, J. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate, 17: 293-300, 1990.
30. Reiner, W. G., Scott, W. W., Eggleston, J. C., and Walsh, P. C. Long-term survival after hormonal therapy for stage D prostatic cancer. J. Urol., 122: 183-184, 1979.
31. Yamamoto, K. R. Steroid receptor regulated transcription of specific genes and gene networks. Annu. Rev. Genet., 19: 209-252, 1985.
32. Burnstein, K. L., and Cidlowski, J. A. Regulation of gene expression by glucocorticoids. Annu. Rev. Physiol., 51: 683-699, 1989.
33. Giguere, V., Hollenberg, S. M., Rosenfeld, M. G., and Evans, R. M. Functional domains of the glucocorticoid receptor. Cell, 46: 645-652, 1986.
34. Hollenberg, S. M., and Evans, R. M. Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell, 55: 899-906, 1988.
35. Umesono, K., and Evans, R. M. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell, 57: 1139-1146, 1989.
36. Danielson, M., Hinck, L., and Ringold, G. M. Two amino acids within the knuckle of the first zinc finger specify DNA response element activation by the glucocorticoid receptor. Cell, 57: 1131-1138, 1989.
37. Murray, R., and Pitt, P. Treatment of advanced prostatic cancer resistant to conventional therapy with aminoglutethimide. Eur. J. Cancer Clin. Oncol., 21: 453-458, 1985.
38. Ponder, B. A. J., Shearer, R. J., Pocock, R. D., Miller, J., Easton, D., Chilvers, C. E. D., Dowsett, M., and Jeffcoate, S. L. Response to aminoglutethimide and cortisone acetate in advanced prostate cancer. Br. J. Cancer, 50: 757-763, 1984.
39. Robinson, M. R. G., Shearer, R. J., and Fergusson, J. D. Adrenal suppression in the treatment of carcinoma of the prostate. Br. J. Urol., 46: 555-559, 1974.
40. Trachtenberg, J. Ketoconazole therapy in advanced prostatic cancer. J. Urol., 137: 959, 1987.
41. Dawson, N. A., Cooper, M. R., Figg, W. D., Headlee, D. J., Thibault, A., Bergan, R. C., Steinberg, S. M., Sausville, E. A., Myers, C. E., and Sartor, O. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer (Phila.), 76: 453-462, 1995.
42. Trachtenberg, J. Optimal testosterone concentration for the treatment of prostatic cancer. J. Urol., 133: 888-890, 1985.
43. Harris, A. L., Dowsett, M., Smith, I. E., and Jeffcoate, S. L. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J. Cancer, 47: 621-627, 1983.
44. 2 181 by aminoglutethimide in advanced breast cancer. Br. J. Cancer, 48: 595-598, 1983.
45. Eichenberger, T., Trachtenberg, J., Toor, P., and Keating, A. Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J. Urol., 141: 190-191, 1989.
46. Marschke, K. B., Ho, K-C., Power, S. G. A., Tan, J-A., Kupfer, S. R., Wilson, E. M., and French, F. S. Response element diversity in androgen regulated genes. In: Dufau, M. L., Isidori, A., and Fabbri, A. (eds.), Cell and Molecular Biology of the Testis, pp. 69-79. New York: Raven Press, 1994.
47. Ho, K-C., Marschke, K. B., Tan, J., Power, S. G., Wilson, E. M., and French, F. S. A complex response element in intron-1 of the androgen regulated 20-kDa protein gene displays cell type-dependent androgen receptor specificity. J. Biol. Chem., 268: 27226-27235, 1993.